The new face of fighting cancer

The battle against cancer has raged for decades and the end game is nearing. Merus’ innovative bispecific antibody therapeutics referred to as Biclonics® are designed to recruit the immune system to kill cancer cells and tip the balance in favor of patients with more effective treatments that have less side effects. Ultimately, it is Merus’ goal to help declare victory for patients with this devastating disease to help them lead normal lives.

Read more

Product Candidates

Human Biclonics®

Biclonics® are designed to possess a format of antibodies that are produced naturally by the immune system, and are designed to retain their favorable attributes including stability, predictability during manufacturing, long half-life and low immunogenicity during treatment of patients.

Read more
MCLA-145 is a full-length human bispecific antibody binding to PD-L1 and CD137 UTRECHT, Netherlands,… 
Merus to retain all global rights outside of China Betta Pharmaceuticals to fund global… 
Clinical milestones for four lead Biclonics® programs expected in 2019 Cash expected to be… 
Merus and Regeneron to cross-license patents relating to certain antibody generation platform technologies Regeneron… 
UTRECHT, The Netherlands, November 8, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company… 
UTRECHT, The Netherlands, September 27, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company… 
Hui Liu, Ph.D., EVP, Chief Business Officer, appointed Head of Merus U.S. Peter B.… 
UTRECHT, The Netherlands, August 30, 2018 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company… 
– Key Oncology and Drug Development Professionals to Support Advancement of Merus’ Pipeline of… 

The new face of fighting cancer

the company's presence in 2018

Upcoming events

Are you interested in meeting the Merus team? Check out where you can find us in 2018 at (international) meetings and events.

All events